Mike Doustdar

Mike Doustdar

business executive unknown

Mike Doustdar has been appointed as the new CEO of Novo Nordisk, taking over from Lars Fruergaard Jørgensen on August 7, following a significant downward revision of the company's sales and operating profit expectations for 2025.

Global Media Ratings
Dominance
0.00%
Persistence
0 wks
Reach
5,045
Power
305$
Sentiment
9.00
Countries Mentioned
Country Mentions Sentiment Dominance + Persistence x Population = Reach x GDP (millions) = Power
Denmark 1 9.00 0.09% +0% 5,792,202 5,045 $350,000 305$
Totals 1 5,792,202 5,045 $350,000 305$
Interactive World Map

Each country's color is based on "Mentions" from the table above.

Recent Mentions

Denmark Denmark: Mike Doustdar is the CEO of Novo Nordisk and commented on the approval of Wegovy as a significant step towards better health for people with obesity. 9

Politiken: Nu er Novos Wegovy-pille godkendt til salg i EU

Denmark Denmark: Mike Doustdar, the CEO of Novo Nordisk, criticized the Wegovy pill copy from Hims and Hers as a waste of money. 3

Politiken: Novo styrtdykker på børsen efter kopi af ny Wegovy-pille

Denmark Denmark: Mike Doustdar explains the challenges Novo Nordisk faces in increasing revenue due to market competition and pricing pressures. 6

Politiken: Vi bliver ramt af to faktorer, der trækker i den forkerte retning

Denmark Denmark: Mike Doustdar, the CEO of Novo Nordisk, explained that the forecast is a result of the company lowering prices on its products significantly. 5

Politiken: Novo Nordisk taber 282 milliarder kroner i markedsværdi

Denmark Denmark: Mike Doustdar explains the challenges Novo Nordisk faces in increasing revenue due to market competition and pricing pressures. 7

Politiken: Vi bliver ramt af to faktorer, der trækker i den forkerte retning

Denmark Denmark: Mike Doustdar, the CEO of Novo Nordisk, explained that the forecast is a result of the company significantly lowering prices on its products. 6

Politiken: Novo Nordisk i blodbad på børsen

Australia Australia: Chief executive Mike Doustdar said in a statement that Novo Nordisk will face pricing headwinds in an increasingly competitive market. 5

The Sydney Morning Herald: Ozempic maker Novo Nordisk faces heavy competition from Mounjaro and other weight loss drugs in Australia

Denmark Denmark: Mike Doustdar is the CEO of Novo Nordisk and acknowledges the challenges the company faces in 2026. 5

Politiken: Hvis Novo får ret, kan 2026 blive selskabets værste år i dette årtusind

Hungary Hungary: Mike Doustdar, the CEO of Novo Nordisk, stated that patients will receive a convenient daily tablet that can help lose as much weight as the original Wegovy injection. 8

Index.hu: Index - Tudomány - Új fejezet a fogyókúrában, engedélyt kapott egy tabletta

United States United States: Mike Doustdar, president and CEO of Novo Nordisk, stated that the Wegovy pill can help patients lose as much weight as the original Wegovy injection. 8

Fox News: FDA has approved first oral GLP-1 weight-loss drug in the US